Company profile
Cybrexa Therapeutics
Changing the paradigm for cancer treatment through the development of antigen-independent peptide drug conjugates.
- Industry
- Biotechnology Research
- Employees
- 11
- Headquarters
- New Haven, CT
- Founded
- 2017
- LinkedIn followers
- 5,266
- Office locations
- 1
Cybrexa Therapeutics company summary
Cybrexa Therapeutics is a company in the Biotechnology Research industry, headquartered in New Haven, CT, founded in 2017. On LinkedIn the company has around 11 employees and 5,266 followers. Its listed specialties include biotech, oncology, Phase I, PARP inhibitor, DDR.
What technology does Cybrexa Therapeutics use?
No technologies detected yet. Warmrank rechecks company websites on a rolling basis.
About Cybrexa Therapeutics
Cybrexa is a clinical-stage oncology biotechnology company developing novel antigen-independent peptide drug conjugates (ADCs) aimed at combatting a range of cancer types, including ovarian, breast and non-small cell lung cancer. With the potential to disrupt the standard of care, the Cybrexa alphalex™ technology is a novel antigen-independent peptide drug conjugate (PDC) platform that enables targeted delivery of highly potent anticancer treatments and aims to revolutionize the standard of care in oncology. The platform consists of a pHLIP® peptide, linker, and small molecule anti-cancer agent. pHLIP® peptides are a family of pH-Low Insertion Peptides that target acidic cell surfaces. pHLIP® was developed at Yale University and the University of Rhode Island, and is exclusively licensed to pHLIP, Inc. alphalex™ represents the disruptive next generation in tumor targeting. Early clinical trials of the company’s lead candidate, CBX-12, demonstrate robust efficacy signals and tolerability in patients with metastatic cancer. As a privately held company, Cybrexa is led by a management team experienced at building life science companies and driven by scientists with an expertise in drug development and oncology. For more information, visit www.cybrexa.com. Community Guidelines: https://bit.ly/3GI6AU0
Specialties
Where is Cybrexa Therapeutics located?
Cybrexa Therapeutics lists 1 location.
Compare companies similar to Cybrexa Therapeutics
More companies in Biotechnology Research.
| Company | Industry | Employees | Founded | Headquarters |
|---|---|---|---|---|
Cybrexa Therapeutics cybrexa.com | Biotechnology Research | 11 | 2017 | New Haven, CT |
 Thermo Fisher Scientific thermofisher.com | Biotechnology Research | 100,779 | - | Waltham, MA |
 Amgen amgen.com | Biotechnology Research | 41,028 | 1980 | Thousand Oaks, CA |
 Biogen biogen.com | Biotechnology Research | 7,742 | - | Cambridge, MA |
 Biocon biocon.com | Biotechnology Research | 11,902 | - | Bangalore, Karnataka |
| Biotechnology Research | 28,679 | - | Bethesda, MD | |
 Genentech gene.com | Biotechnology Research | 18,296 | 1976 | South San Francisco, California |
 Eurofins eurofins.com | Biotechnology Research | 24,928 | - | Luxembourg, Luxembourg |
 Gilead Sciences gilead.com | Biotechnology Research | 14,743 | - | Foster City, CA |
 Syneos Health syneoshealth.com | Biotechnology Research | 23,772 | - | Morrisville, NC |
 Moderna modernatx.com | Biotechnology Research | 6,238 | 2010 | Cambridge, Massachusetts |
Frequently asked questions about Cybrexa Therapeutics
What does Cybrexa Therapeutics do?
Cybrexa is a clinical-stage oncology biotechnology company developing novel antigen-independent peptide drug conjugates (ADCs) aimed at combatting a range of cancer types, including ovarian, breast and non-small cell lung cancer. With the potential to disrupt the standard of care, the Cybrexa alphalex™ technology is a novel antigen-independent peptide drug conjugate (PDC) platform that enables targeted delivery of highly potent anticancer treatments and aims to revolutionize the standard of care in oncology. The platform consists of a pHLIP® peptide, linker, and small molecule anti-cancer agent. pHLIP® peptides are a family of pH-Low Insertion Peptides that target acidic cell surfaces. pHLIP® was developed at Yale University and the University of Rhode Island, and is exclusively licensed to pHLIP, Inc. alphalex™ represents the disruptive next generation in tumor targeting. Early clinical trials of the company’s lead candidate, CBX-12, demonstrate robust efficacy signals and tolerability in patients with metastatic cancer. As a privately held company, Cybrexa is led by a management team experienced at building life science companies and driven by scientists with an expertise in drug development and oncology. For more information, visit www.cybrexa.com. Community Guidelines: https://bit.ly/3GI6AU0
How many employees does Cybrexa Therapeutics have?
Cybrexa Therapeutics has around 11 employees on LinkedIn.
Where is Cybrexa Therapeutics headquartered?
Cybrexa Therapeutics is headquartered in New Haven, CT.
When was Cybrexa Therapeutics founded?
Cybrexa Therapeutics was founded in 2017.
Build a lead list from companies like Cybrexa Therapeutics
Describe your ICP or import a CSV. Warmrank finds matching companies, enriches contacts with verified emails, and tracks every lead.